Company profile

Fortis Therapeutics, Inc.

Privately held: no public share price (Bay Area ADC biotech (anti-CD46 FOR46) developed from UCSF-licensed technology; closed a $40M Series A in 2021 (BusinessWire). FibroGen (now Kyntra Bio, roster company_id 200) holds a licensing/acquisition option but has not exercised it per BioPharma Dive coverage -- Fortis remains an independent private company. Sources: https://clinicaltrials.gov/study/NCT03650491 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://api.gleif.org/api/v1/lei-records/254900ESD9GZFY66OR92 ; https://api.gleif.org/api/v1/lei-records/549300NIGKDV9203Q946 ; https://api.gleif.org/api/v1/lei-records/5493007DSIFXCC6J0N24 Entity resolved by asset-pipeline-v2.)